Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06028477 · ClinicalTrials.gov registry record · NA

Vibrotactile Coordinated Reset in Parkinson's Disease - Proof of Concept Study

A NA study, sponsored by Stanford University.

Not yet
Registry status
NA
Development phase
34
Enrollment target

NCT06028477: Clinical Trial NA study, sponsored by Stanford University.

NCT06028477 is a NA study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06028477, a NA study, has not yet begun recruiting, sponsored by Stanford University.

NOT YET RECRUITING
Registry status
NA
Development phase
34 participants
Enrollment target

Study Summary

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on Parkinson's symptoms. vCR will be administered with a device called the Stanford Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as Levodopa and/or deep brain stimulation. Patients will be followed for 14 months.

Primary Outcome

Mean change in the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score. Minimum score - 0 indicates normal functioning Maximum score - 132 indicated severe impairment Lower scores indicate greater functionality and higher scores indicate severe impairment in functionality.

Interventions

  • DEVICE Stanford Glove

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2025-01-10
Est. Completion 2027-03-01
Phase NA
Stanford University

1,744 total trials

What is known before NCT06028477 opens enrollment

NCT06028477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Stanford Glove is the first listed.

NCT06028477 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06028477 about?

NCT06028477 is a clinical study titled "Vibrotactile Coordinated Reset in Parkinson's Disease - Proof of Concept Study". The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on Parkinson's symptoms. vCR will be administered with a device called the Stanford Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments s...

What is the current status of trial NCT06028477?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2025-01-10. Estimated completion is 2027-03-01.

What interventions are being tested in trial NCT06028477?

The interventions under investigation include: Stanford Glove (DEVICE).

Who is sponsoring clinical trial NCT06028477?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06028477's enrollment target sits among peer trials

34 1570th of 2000 higher than 427 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06028477, the US trial registry maintained by the National Library of Medicine. NCT06028477 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.